Genocea Biosciences, Inc.

Symbol: GNCA




Market price today

  • -0.0004

    P/E Ratio

  • 0.0000

    PEG Ratio

  • 0.01M

    MRK Cap

  • 0.00%

    DIV Yield

Genocea Biosciences, Inc. (GNCA) Stock Price & Analysis

Shares Outstanding


Gross Profit Margin


Operating Profit Margin


Net Profit Margin


Return on Assets


Return on Equity


Return on Capital Employed


Company general description and statistics

Sector: Healthcare
Industry: Biotechnology
CEO:Mr. William Clark
Full-time employees:74
Address:100 Acorn Park Dr

Genocea Biosciences, Inc., a biopharmaceutical company, discovers and develops novel cancer immunotherapies. The company uses its proprietary discovery platform, ATLAS, which profiles each patient's CD4+ and CD8+ T cell immune responses to every target or antigen identified by next-generation sequencing of that patient's tumor. Its products include GEN-011, an adoptive T cell therapy, which is in Phase 1/2a clinical trials for the treatment of solid tumors; and GEN-009, a neoantigen vaccine candidate, which is in Phase 1/2a clinical trials that delivers adjuvanted synthetic long peptides spanning ATLAS-identified anti-tumor neoantigens. The company was incorporated in 2006 and is based in Cambridge, Massachusetts. On July 5, 2022, Genocea Biosciences, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Massachusetts.

General Outlook

In simple terms, Genocea Biosciences, Inc. has 58.783 M shares that people are buying and selling right now. When we look at how much money they make before expenses, they keep 1.000% as profit. This shows they're good at controlling costs and are financially stable. Their operating profit, which is money made from regular business activities, is -31.745%. This means they run their business efficiently. Lastly, after paying all their bills, they still have a profit of -9.397%. This tells us they're good at keeping money after all costs.

Return on Investments

The company's asset efficiency, represented by a robust -0.276% return, is a testament to Genocea Biosciences, Inc.'s adeptness in optimizing resource deployment. Genocea Biosciences, Inc.'s utilization of its assets to generate profits is strikingly evident through a noteworthy return on equity of -0.855%. Furthermore, the proficiency of Genocea Biosciences, Inc. in capital utilization is underscored by a remarkable -1.397% return on capital employed.

Stock Prices

Genocea Biosciences, Inc.'s stock prices have been subject to undulating patterns. The peak stock value during this interval surged to $0.0074, while its low point bottomed out at $0.0011. This variance in figures offers investors a lucid insight into the roller-coaster ride that is Genocea Biosciences, Inc.'s stock market.

Liquidity Ratios

Analyzing GNCA liquidity ratios reveals its financial health of the firm. The current ratio of 223.85% gauges short-term asset coverage for liabilities. The quick ratio (198.83%) assesses immediate liquidity, while the cash ratio (198.83%) indicates cash reserves.

Current Ratio223.85%
Quick Ratio198.83%
Cash Ratio198.83%

Profitability Ratios

GNCA profitability indicators offer a lens into its earnings landscape. A pretax profit margin of -2022.91% underscores its earnings before tax deductions. The effective tax rate stands at 53.55%, revealing its tax efficiency. The net income per EBT, 46.45%, and the EBT per EBIT, 63.72%, provide insights into its earnings hierarchy. Lastly, with an EBIT per revenue ratio of -3174.47%, we grasp its operational profitability.

Pretax Profit Margin-2022.91%
Effective Tax Rate53.55%
Net Income per EBT46.45%
EBT per EBIT63.72%
EBIT per Revenue-3174.47%

Operational Efficiency

Operational metrics shed light on its business agility. With an operating cycle of 2.24, it details the span from stock purchase to revenue. The 2 days it takes to settle debts showcases its creditor relations.

Days of Sales Outstanding199
Fixed Asset Turnover0.12
Asset Turnover0.03

Cash Flow Ratios

Peering into the cash flow metrics reveals liquidity and operational efficiency. The operating cash flow per share, -0.66, and free cash flow per share, -0.71, depict cash generation on a per-share basis. The cash per share value, 0.54, showcases liquidity position. Lastly, the operating cash flow sales ratio, -27.65, offers insight into cash flow relative to sales.

Operating Cash Flow per Share-0.66
Free Cash Flow per Share-0.71
Cash per Share0.54
Operating Cash Flow Sales Ratio-27.65
Free Cash Flow to Operating Cash Flow Ratio1.07
Cash Flow Coverage Ratio-4.08
Short Term Coverage Ratio-6.49
Capital Expenditure Coverage Ratio-13.80
Dividend Paid and Capex Coverage Ratio-13.80

Debt and Leverage Ratios

Diving into debt and leverage metrics unveils the company's financial structure. The debt ratio, at 19.89%, highlights its total liabilities relative to assets. With a debt-equity ratio of 0.41, we discern the balance between debt and equity financing. The long-term debt to capitalization, 13.28%, and total debt to capitalization, 29.14%, ratios shed light on its capital structure. An interest coverage of 46.47 indicates its ability to manage interest expenses.

Debt Ratio19.89%
Debt Equity Ratio0.41
Long Term Debt to Capitalization13.28%
Total Debt to Capitalization29.14%
Interest Coverage46.47
Cash Flow to Debt Ratio-4.08
Company Equity Multiplier2.07

Per Share Data

Speaking about the per share data offers a perceptive view of financial distribution. The revenue per share, 0.02, provides a glimpse into top-line earnings distributed across each share. Net income per share, -0.22, reflects the portion of profit attributed to each share. The book value per share, 0.39, represents the net asset value distributed per share, while the tangible book value per share, 0.39, excludes intangible assets.

Revenue Per Share0.02
Net Income Per Share-0.22
Book Value Per Share0.39
Tangible Book Value Per Share0.39
Shareholders Equity Per Share0.39
Interest Debt Per Share0.15
Capex Per Share-0.05

Other Metrics

Venturing into other key metrics unveils diverse facets of financial performance. The enterprise value, 53,532,000, captures the company's total value, considering both debt and equity. Income quality, 1.37, assesses the reliability of reported earnings. The sales, general, and administrative to revenue ratio, 8.97, gauges operational efficiency, while the research and development to revenue, 2377.82%, highlights investment in innovation.

Enterprise Value53,532,000
Income Quality1.37
Sales General and Administrative to Revenue8.97
Research and Development to Revenue2377.82%
Capex to Operating Cash Flow7.25%
Capex to Revenue-200.37%
Capex to Depreciation-211.18%
Stock-Based Compensation to Revenue221.51%
Graham Number1.41
Return on Tangible Assets-27.55%
Graham Net Net0.12
Working Capital23,139,000
Tangible Asset Value27,075,000
Net Current Asset Value12,930,000
Average Payables517,000
Trusted project
“All information displayed on the site is verified. High quality project and financial performance”
Eugene Alexeev
NumFin Founder and investing enthusiast

Frequently Asked Question

How many company shares are outstanding in 2024?

There are stock number shares outstanding of Genocea Biosciences, Inc. (GNCA) on the NASDAQ in 2024.

What is P/E ratio of enterprise in 2024?

The current P/E ratio of enterprise is -0.000 in 2024.

What is the ticker symbol of Genocea Biosciences, Inc. stock?

The ticker symbol of Genocea Biosciences, Inc. stock is GNCA.

What is company IPO date?

IPO date of Genocea Biosciences, Inc. is 2014-02-05.

What is company current share price?

Current share price is 0.000 USD.

What is stock market cap today?

The market cap of stock today is 5878.000.

What is PEG ratio in 2024?

The current 0.000 is 0.000 in 2024.

What is the number of employees in 2024?

In 2024 the company has 74.